• Patent Title: 1-(2,6-diazaspiro[3.3]heptan-6-yl)-5,6-dihydro-4h-benzo[f][1,2,4]triazolo[4,3-A][1,4]diazepine derivatives and related compounds as vasopressin antagonists for the treatment of neuro-psychological disorders
  • Application No.: US17311974
    Application Date: 2019-12-12
  • Publication No.: US12247037B2
    Publication Date: 2025-03-11
  • Inventor: Gary Brandt
  • Applicant: Neumora Therapeutics, Inc.
  • Applicant Address: US MA Watertown
  • Assignee: Neumora Therapeutics, Inc.
  • Current Assignee: Neumora Therapeutics, Inc.
  • Current Assignee Address: US MA Watertown
  • Agency: Seed IP Law Group LLP
  • International Application: PCT/US2019/066082 WO 20191212
  • International Announcement: WO2020/123872 WO 20200618
  • Main IPC: C07D519/00
  • IPC: C07D519/00 A61P25/22
1-(2,6-diazaspiro[3.3]heptan-6-yl)-5,6-dihydro-4h-benzo[f][1,2,4]triazolo[4,3-A][1,4]diazepine derivatives and related compounds as vasopressin antagonists for the treatment of neuro-psychological disorders
Abstract:
The present invention relates to 1-(2,6-diazaspiro[3.3]heptan-6-yl)-5,6-dihydro-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine derivatives and related compounds of Formula (I): wherein A, B, G, R1, R1b, RiC, R2 and X are as defined herein. The present compounds are vasopressin receptor antagonists (in particular of the Via receptor) for the treatment of neuro-psychological disorders, such as e.g. autism, anxiety, stress-related disorders, depression, schizophrenia or bipolar disorder. The present description discloses the synthesis of exemplary compounds, as well as pharmacological data thereof (e.g. pages 71 to 246; examples 1 to 49; tables 1 to 5). An exemplary compound is e.g. 8-chloro-1-(2-(5-fluoropyridin-2-yl)-2,6-diazaspiro[3.3]heptan-6-yl)-5-methyl-5,6-dihydro-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine (example 1, compound no. 1).
Information query
Patent Agency Ranking
0/0